These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 12647444)
41. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. Bhowmick S; Hazra A; Ghosh M Aust N Z J Psychiatry; 2010 Mar; 44(3):237-42. PubMed ID: 20050717 [TBL] [Abstract][Full Text] [Related]
42. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Ramasubbu R; Ravindran A; Lapierre Y Pharmacopsychiatry; 2000 Nov; 33(6):236-8. PubMed ID: 11147933 [TBL] [Abstract][Full Text] [Related]
44. [Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression]. Weimer E; Braus DF; Cavus I; Thome J Fortschr Neurol Psychiatr; 2002 Apr; 70(4):210-7. PubMed ID: 11948436 [TBL] [Abstract][Full Text] [Related]
45. Switching clozapine responders to olanzapine. Littrell KH; Johnson CG; Hilligoss NM; Peabody CD; Littrell SH J Clin Psychiatry; 2000 Dec; 61(12):912-5. PubMed ID: 11206595 [TBL] [Abstract][Full Text] [Related]
46. High-dose olanzapine for treatment-refractory schizophrenia. Lerner V Clin Neuropharmacol; 2003; 26(2):58-61. PubMed ID: 12671523 [TBL] [Abstract][Full Text] [Related]
47. [Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results]. Meder J; Debowska G; Lis J; Araszkiewicz A; Sierosławska K; Kolesaric A; Treuer T Psychiatr Pol; 2004; 38(3):469-84. PubMed ID: 15199656 [TBL] [Abstract][Full Text] [Related]
48. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Miller TJ; Zipursky RB; Perkins D; Addington J; Woods SW; Hawkins KA; Hoffman R; Preda A; Epstein I; Addington D; Lindborg S; Marquez E; Tohen M; Breier A; McGlashan TH Schizophr Res; 2003 May; 61(1):19-30. PubMed ID: 12648732 [TBL] [Abstract][Full Text] [Related]
49. [Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients]. MMW Fortschr Med; 2003 May; 145 Suppl 2():86-7. PubMed ID: 14579491 [No Abstract] [Full Text] [Related]
50. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. Lindenmayer JP; Volavka J; Lieberman J; Sheitman B; Citrome L; Chakos M; Czobor P; Parker B; Iskander A J Clin Psychopharmacol; 2001 Aug; 21(4):448-53. PubMed ID: 11476131 [TBL] [Abstract][Full Text] [Related]
51. Olanzapine augmentation of clozapine. Gupta S; Sonnenberg SJ; Frank B Ann Clin Psychiatry; 1998 Sep; 10(3):113-5. PubMed ID: 9781474 [TBL] [Abstract][Full Text] [Related]
52. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Kinon BJ; Hill AL; Liu H; Kollack-Walker S Int J Neuropsychopharmacol; 2003 Jun; 6(2):97-102. PubMed ID: 12890301 [TBL] [Abstract][Full Text] [Related]